Table 2.

Adverse events induced by bevacizumab in bevacizumab+ group (n = 18).

Adverse Events	Grade
	0		1		2		3		4
Hypertension	4	22%	4	22%	6	33%	4	22%	0
Proteinuria	8	44%	5	28%	1	6%	4	22%	0
Bleeding	12	67%	5 a	28%	0		1 b	6%	0
Colonic obstruction	16	89%	0	0%	0		2	11%	0
Thromboemboic events	18		0		0		0		0
Gastrointestinal perforation	18		0		0		0		0
Wound dehiscence	18		0		0		0		0
Fistula	18		0		0		0		0

^a: nasal bleeding, ^b: anal hemorrhage.